148 related articles for article (PubMed ID: 19217461)
1. Independent determinants of soluble form of receptor for advanced glycation end products in elderly hypertensive patients.
Nakamura K; Adachi H; Matsui T; Kurita Y; Takeuchi M; Yamagishi S
Metabolism; 2009 Mar; 58(3):421-5. PubMed ID: 19217461
[TBL] [Abstract][Full Text] [Related]
2. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
Tan KC; Shiu SW; Chow WS; Leng L; Bucala R; Betteridge DJ
Diabetologia; 2006 Nov; 49(11):2756-62. PubMed ID: 16969649
[TBL] [Abstract][Full Text] [Related]
3. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.
Yamagishi S; Adachi H; Nakamura K; Matsui T; Jinnouchi Y; Takenaka K; Takeuchi M; Enomoto M; Furuki K; Hino A; Shigeto Y; Imaizumi T
Metabolism; 2006 Sep; 55(9):1227-31. PubMed ID: 16919543
[TBL] [Abstract][Full Text] [Related]
4. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients.
Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Ueda Y; Suzuki T; Yamada S; Takeuchi M; Fukami K; Ueda S; Adachi H; Matsui T; Okuda S; Yamagishi S
Metabolism; 2009 Nov; 58(11):1624-8. PubMed ID: 19604520
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.
Nakamura K; Yamagishi S; Adachi H; Kurita-Nakamura Y; Matsui T; Yoshida T; Imaizumi T
Mol Med; 2007; 13(3-4):185-9. PubMed ID: 17592553
[TBL] [Abstract][Full Text] [Related]
6. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes.
Tam XH; Shiu SW; Leng L; Bucala R; Betteridge DJ; Tan KC
Clin Sci (Lond); 2011 Jan; 120(2):81-9. PubMed ID: 20726839
[TBL] [Abstract][Full Text] [Related]
7. Association of the receptor for advanced glycation end products (RAGE) -374 T/A gene polymorphism and circulating soluble RAGE with nephropathy in type 1 diabetic patients.
Abdel-Azeez HA; El-Okely AM
Egypt J Immunol; 2009; 16(1):95-106. PubMed ID: 20726326
[TBL] [Abstract][Full Text] [Related]
8. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.
Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
Diabetes Metab Res Rev; 2008 Feb; 24(2):109-14. PubMed ID: 17694504
[TBL] [Abstract][Full Text] [Related]
9. Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function.
Kajikawa M; Nakashima A; Fujimura N; Maruhashi T; Iwamoto Y; Iwamoto A; Matsumoto T; Oda N; Hidaka T; Kihara Y; Chayama K; Goto C; Aibara Y; Noma K; Takeuchi M; Matsui T; Yamagishi S; Higashi Y
Diabetes Care; 2015 Jan; 38(1):119-25. PubMed ID: 25336748
[TBL] [Abstract][Full Text] [Related]
10. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans.
Jang Y; Kim JY; Kang SM; Kim JS; Chae JS; Kim OY; Koh SJ; Lee HC; Ahn CW; Song YD; Lee JH
Metabolism; 2007 Feb; 56(2):199-205. PubMed ID: 17224333
[TBL] [Abstract][Full Text] [Related]
11. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients.
Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Yasuda T; Yamasaki Y
Diab Vasc Dis Res; 2008 Sep; 5(3):190-7. PubMed ID: 18777492
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
[TBL] [Abstract][Full Text] [Related]
13. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease.
Nakamura K; Yamagishi S; Adachi H; Kurita-Nakamura Y; Matsui T; Yoshida T; Sato A; Imaizumi T
Diabetes Metab Res Rev; 2007 Jul; 23(5):368-71. PubMed ID: 17024691
[TBL] [Abstract][Full Text] [Related]
14. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.
Basta G; Sironi AM; Lazzerini G; Del Turco S; Buzzigoli E; Casolaro A; Natali A; Ferrannini E; Gastaldelli A
J Clin Endocrinol Metab; 2006 Nov; 91(11):4628-34. PubMed ID: 16926247
[TBL] [Abstract][Full Text] [Related]
15. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension.
Geroldi D; Falcone C; Emanuele E; D'Angelo A; Calcagnino M; Buzzi MP; Scioli GA; Fogari R
J Hypertens; 2005 Sep; 23(9):1725-9. PubMed ID: 16093918
[TBL] [Abstract][Full Text] [Related]
16. Plasma sRAGE is not associated with urinary microalbumin excretion in type 2 diabetic nephropathy at the early stage.
Yu JY; An XF; Liu JS; Ten SC; Wang X; Zhao Y; Huang S; Gu WJ; Gao F
Diabetes Res Clin Pract; 2010 Feb; 87(2):157-60. PubMed ID: 19945761
[TBL] [Abstract][Full Text] [Related]
17. Association of soluble receptor for advanced glycation end-product with increasing central aortic stiffness in hypertensive patients.
Yoon SJ; Park S; Park C; Chang W; Cho DK; Ko YG; Choi D; Kwon HM; Jang Y; Chung N
Coron Artery Dis; 2012 Mar; 23(2):85-90. PubMed ID: 22198512
[TBL] [Abstract][Full Text] [Related]
18. Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study.
Melin EO; Dereke J; Hillman M
Lipids Health Dis; 2020 Oct; 19(1):223. PubMed ID: 33054750
[TBL] [Abstract][Full Text] [Related]
19. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes.
Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Yasuda T; Umayahara Y; Kosugi K; Yamasaki Y
Atherosclerosis; 2009 May; 204(1):288-92. PubMed ID: 18926539
[TBL] [Abstract][Full Text] [Related]
20. Placental growth factor, pregnancy-associated plasma protein-A, soluble receptor for advanced glycation end products, extracellular newly identified receptor for receptor for advanced glycation end products binding protein and high mobility group box 1 levels in patients with acute kidney injury: a cross sectional study.
Zakiyanov O; Kriha V; Vachek J; Zima T; Tesar V; Kalousova M
BMC Nephrol; 2013 Nov; 14():245. PubMed ID: 24188108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
